Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP
Tweet Send to a Friend
Seaport Therapeutics (Nasdaq: SPTX) presented Phase 1 pharmacokinetic (PK) data for its drug candidate GlyphAgo at the 39th European College ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




